

# Dynamic Allocation in Clinical Trials: Past, Present, and Future

Palash Sharma; University of Kansas Medical Center

Tina Young, Bristol Myers Squibb

## Introduction

### Motivated by Oncology Landscape

- ❖ Crowded → encourages personalized medicine approach to identify characteristics of patients.
- ❖ Combination therapies → as a “backbone” treatment is established, the next wave of development includes add-on therapies.
- ❖ Emerging unmet medical need often in later lines of therapy which may have diverse earlier lines.

### Impact on Newer Trials

- ❖ “Just add it as a stratification factor” is often suggested in discussions (e.g., biomarker status, prior response to backbone therapy, prior exposure to X, Y, or Z).
- ❖ There may already be existing clinical factors thought to influence treatment that warrant stratification
- ❖ Interest in balancing randomization across arms, but difficult to reduce to reasonable size.

## Motivating Example

Phase 2 trial of Nivolumab + Relatlimab vs. mono therapy of Nivolumab.

Stratification wanted on:

- Region (Asia/ Non-Asia)
- Biomarker Expression (Lag 3 +/-)
- Clinical factor (MVI +/-)

Primary endpoint is objective response rate (ORR).

→ 1:1 and 2:1 allocation was considered for 2 arm trial

→ 2:1:2 allocation ratio was considered for 3 arm trial

## Methods

### Simple Randomization

- ❖ Conceptually, it is the simplest and most robust method
- ❖ This method does not guarantee equal distribution of treatment assignment.

### Stratified Block Randomization

- ❖ Better control of Type 1 error for certain situations (e.g., adaptive allocation ratios, interactions between stratification variables)
- ❖ May lead predictability issue.
- ❖ Easier for recruitment and lower implementation cost
- ❖ Balances specified and unspecified covariates, including temporal effects

### Dynamic Allocation (Minimization)

- ❖ Minimization, a form of restricted randomization procedure.
- ❖ The minimization procedure maintains marginal balance for each stratum rather than attempting to achieve overall balance.
- ❖ Allow unequal allocation ratio (e.g., 2:1)
- ❖ Valid alternative for small-to-moderate sized trials with multiple significant prognostic factors having moderate to large treatment effects
- ❖ Makes treatment allocations unpredictable

### Hybrid Minimization Approaches

Two novel approaches were proposed based on Minimization method.

- ❖ Approach 1: Alternating Minimization (Use Minimization + Simple randomization)
- ❖ Approach 2: Stratified Nested Minimization (Minimization + Permuted Block randomization)

Let  $n_{ijk}$  be the number of patients already assigned to treatment group  $k$  where  $k = 1, 2, \dots, K$  at strata level  $j$  ( $j = 1, 2, \dots, J$ ) of the covariate  $i$  ( $i = 1, 2, \dots, C$ ). (Kuznetsova and Tymofeyev, 2012, Jin et al., 2019) Assume the next patients is ready to allocate.

- ❖ Calculate the number of participants on each level of the covariates  $i$  ( $i = 1, 2, \dots, C - 1$ ) for the new patients  $n_{ir_ik}$  is allocated to each treatment group  $k$ .

- ❖ Next, we will measure the resulting total imbalance by the range (RG):

$$G_{RG} = \sum_{i=1}^C RG \left[ \frac{n_{ir_1i}}{a_1}, \frac{n_{ir_2i}}{a_2}, \dots, \frac{n_{ir_ki}}{a_k} \right]$$

- ❖ This new subject will hypothetically be assigned to the  $k^{\text{th}}$  treatment group with  $G_k = \min(G_1, G_2, \dots, G_k)$  with a high probability  $p$  and equally distributed to any  $k - 1$  groups with probability  $\frac{1-p}{k-1}$ .

- ❖ Record the hypothetical treatment assignment for each participant using biased coin minimization approach and create a new stratifying variable (S) based on C-1 covariate and the hypothetical treatment assignment as mentioned in previous steps.

- ❖ For this new stratifying covariates (S and C), we will use stratified permuted block randomization with equal / unequal block sizes.

- ❖ For example, In case of two arm trial, we will have new stratifying variable based on  $G_{RG} > 0$  vs.  $G_{RG} < 0$  vs.  $G_{RG} = 0$ . If the  $C^{\text{th}}$  have 2 factors, then the combined new strata will be 6.

## Simulation Design

Table 1: Randomization designs selected for the simulation study

Design	Tuning Parameter	Method	Total No of Design
Simple randomization	N/A	N/A	1
Permuted Block Randomization	Block size = 4 (1:1), 3(2:1) 5(2:1:2)	N/A	1
Minimization Approach	P = 0.80, 0.90	Range/SD	4
Alternating Minimization	P = 0.80, 0.90	Range/SD	4
Stratified nested Minimization	P = 0.80, 0.90	Range/SD	4

### Design Parameter:

- ❖ 2 arm with 1:1 or 2:1 allocation ratio (N=200)
- ❖ 3 arm trial with 2:1:2 allocation ratio (N=250)
- ❖ To evaluate the type I error and power of randomization procedure, we apply stratified Cochran-Mantel-Haenszel (CMH) test.
- ❖ For two arm trial, type I error rate was calculated with the proportion of response is same in both arms i.e.,  $p_1 = p_2 = 0.3$  and the power was calculated with  $p_1 = 0.50, p_2 = 0.30$ .
- ❖ For Minimization based approach, re-randomization test was implemented and recommended.

## Results

Table: Compare the balancing property n (%) at each level of covariates using the Stratified Nested minimization method for different allocation ratios and  $p = 0.90$  and Range Method is considered.

Allocation ratio	Method	Range			SD		
		Treatment			Treatment		
		Arm A	Arm B	Arm C	Arm A	Arm B	Arm C
1:1	Lag3+	49.99	50.03		49.94	50.03	
	Lag3-	50.01	49.97		50.06	49.96	
	Region(A)	49.96	49.96		50.08	49.99	
	Region (N- A)	50.05	50.04		49.92	50.01	
	MVI (Y)	49.88	49.97		50.04	49.93	
	MVI (N)	50.13	50.02		49.97	50.06	
2:1	Lag3+	66.68	33.37		66.65	33.28	
	Lag3-	66.59	33.32		66.69	33.38	
	Region(A)	66.67	33.32		66.68	33.34	
	Region (N- A)	66.64	33.37		66.66	33.33	
	MVI (Y)	66.63	33.38		66.65	33.30	
	MVI (N)	66.68	33.31		66.66	33.36	
2:1:2	Lag3+	49.99	24.99	50.01	49.97	25.07	49.97
	Lag3-	49.99	25.01	50.01	50.06	25.05	49.91
	Region(A)	49.98	24.95	50.01	49.95	25.07	49.95
	Region (N- A)	50.01	25.06	50.00	50.04	25.05	49.93
	MVI (Y)	49.93	24.99	50.01	50.04	25.05	49.94
	MVI (N)	50.06	25.01	49.96	49.96	25.08	49.94

Table: Simulation of the overall relative imbalance and Type I error and Power for different randomization procedures using the stratified CMH test

Method	Prob. of assignment	1:1 (N = 200)				2:1 (N = 200)				2:1:2 (N = 250)			
		Imbalance	Type I error	Power	Total Imbalance	Type I error	Power	Total Imbalance	Type I error	Power	Total Imbalance	Type I error	Power
SR	N/A	0.239	0.050	0.821	0.170	0.047	0.772	0.166	0.048	0.732			
Block Rand	N/A	0.170	0.049	0.824	0.122	0.048	0.777	0.117	0.049	0.730			
Minimization	0.90 (RN)	0.170	0.049	0.828	0.122	0.045	0.783	0.118	0.052	0.736			
Alternating	0.90 (RN)	0.235	0.053	0.822	0.165	0.050	0.778	0.164	0.048	0.742			
Stratified Nested	0.90 (RN)	0.170	0.045	0.831	0.121	0.051	0.774	0.118	0.052	0.730			
Minimization	0.80 (RN)	0.171	0.047	0.833	0.123	0.051	0.783	0.119	0.050	0.737			
Alternating	0.80 (RN)	0.237	0.056	0.807	0.169	0.050	0.779	0.163	0.046	0.741			
Stratified Nested	0.80 (RN)	0.170	0.062	0.826	0.121	0.051	0.783	0.118	0.052	0.738			
Minimization	0.90 (SD)	0.171	0.055	0.835	0.121	0.052	0.776	0.118	0.048	0.745			
Alternating	0.90 (SD)	0.237	0.052	0.824	0.166	0.050	0.775	0.162	0.051	0.740			
Stratified Nested	0.90 (SD)	0.172	0.052	0.819	0.121	0.047	0.784	0.119	0.054	0.746			
Minimization	0.80 (SD)	0.172	0.052	0.829	0.124	0.046	0.786	0.118	0.049	0.740			
Alternating	0.80 (SD)	0.238	0.046	0.826	0.167	0.049	0.772	0.162	0.047	0.738			
Stratified Nested	0.80 (SD)	0.171	0.049	0.830	0.121	0.052	0.774	0.119	0.046	0.748			

All the simulation ran for 10,000 times; Type I error calculated using the  $p_1 = p_2 = 0.30$ ; Power was calculated using the  $p_1 = 0.50, p_2 = 0.30$ ; For 3 arms, Power was calculated using the  $p_1 = 0.50, p_2 = 0.40, p_3 = 0.30$ ; RN indicate Range and SD indicate Standard Deviation was considered

### Re-randomization test

- ❖ Compute the test statistics of the CMH test for the observed responses using the randomization approach for treatment assignment.
- ❖ Reallocate the treatment assignment in accordance with the given randomization procedure.
- ❖ Reobtain the test statistics  $T$  for this reallocation and obtain reference test statistics.
- ❖ Repeat steps 2 and 3 for  $R$  repeated number of times.
- ❖ The P-value of the re-randomization test can be estimated by the Monte-Carlo method.

Method	1:1 (N = 200)		2:1 (N = 200)		2:1:2 (N = 250)	
	Type I error	Power	Type I error	Power	Type I error	Power
SR	0.054	0.819	0.048	0.769	0.051	0.734
Block Rand	0.049	0.822	0.051	0.776	0.046	0.738
Minimization	0.051	0.824	0.051	0.770	0.050	0.743
Alternating	0.051	0.817	0.049	0.774	0.049	0.738
Stratified Nested	0.049	0.821	0.051	0.773	0.050	0.735

All the simulation ran for 10,000 times with  $R = 1000$  repetitions; Type I error calculated using the  $p_1 = p_2 = 0.30$ ; And Power was calculated using the  $p_1 = 0.50, p_2 = 0.30$ ; For 3 arms, Power was calculated using the  $p_1 = 0.50, p_2 = 0.40, p_3 = 0.30$

SR = Simple Randomization

## Conclusions

- ❖ Provide a brief summary of various randomization approach
- ❖ Propose a novel hybrid approaches that combines the strength of each existing methods without their drawbacks
- ❖ Hybrid approaches enables balance of additional stratification variables while maintaining balance.
- ❖ Stratified Nested Minimization method offer an alternative method which allow prioritization of the Cth variable for marginal balancing while minimizing the imbalance on the remaining C-1 variables.

## Bibliography

1. Kuznetsova OM, Tymofeyev Y. Preserving the allocation ratio at every allocation with biased coin randomization and minimization in studies with unequal allocation. Statistics in Medicine. 2012 Apr 13;31(8):701-23.
2. Sangro B, et al.. P-61 Relatlimab+ nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073. Annals of Oncology. 2021 Jul 1;32:S117.
3. Jin M, Polis A, Hartzel J. Algorithms for minimization randomization and the implementation with an R package. Communications in Statistics-Simulation and Computation. 2019 May 30:1-1.

## Acknowledgement

I would like to thank BMS and my manager Dr. Tina Young for giving me the opportunity to work on this exciting summer intern project.